individuals taking specific antipsychotic medications may develop TD.1
symptoms can appear after starting these medications.2
Screening for TD is often delayed — or skipped altogether. Failing to screen routinely puts patients at risk of undetected progression and exposes providers to clinical liability and compliance gaps. In today’s behavioral health landscape, meeting screening standards isn’t optional — it’s essential.
Provider Sign Up“There’s always that doubt—‘Did I really see dyskinesia or was that just normal movement?’ TDScreen helps me make confident, evidence-based decisions.”
Clinically Validated
Published in the Journal of Clinical Psychiatry, a peer-reviewed study across 356 participants found that TDScreen’s AI achieved an AUC of 0.89 and surpassed the sensitivity and specificity of trained clinicians using the standard AIMS assessment.
How It Works
The TDScreen tool is based on the Abnormal Involuntary Movement Scale (AIMS), a comprehensive clinician-rated scale designed to specifically evaluate orofacial movements. Employing advanced AI video technology, TDScreen efficiently assesses and quantifies symptom presence and severity of tardive dyskinesia in less than 5 minutes. The resulting score generated by this screening can aid in clinical decision-making and management strategies.
Provider Sign Up
Request access and grant us permission to securely share patient screening results with you.
Collaborate with our team to enroll your eligible patients for regular automated screenings.
Results appear in your HIPAA-compliant provider portal and can help inform follow-up.
Patients are automatically notified to screen every 4 months, or at the frequency you choose.
Immediate action not likely needed. Re-screen in 4–6 months to continue monitoring.
Monitor this patient continually for TD. Administer follow-up TDScreen sessions at regular intervals.
Perform a full in-person AIMS assessment with the patient and discuss treatment options.
Patient should retake TDScreen, making sure all assessment steps are fully completed.
The Patient Experience
TDScreen guides patients through a simple, non-intimidating 5-minute video assessment on their own device. No app download required — just a link you share.
Among 2,000+ patients screened with TDScreen, 80% of those diagnosed with TD were prescribed treatment…
Read Article →
Early detection and diagnosis offer the best chance to reduce the long-term impact TD can have…
Read Article →
A hidden placebo response to watch for when patients stop meds on their own…
Read Article → The first automated, video-based screening tool for tardive dyskinesia, available at no cost to providers…
Read Article →
Available free to National Council for Mental Wellbeing members and behavioral health providers…
Read Article →Clinicians can access our FREE online platform, TDScreen, designed to streamline TD risk assessment and improve patient care.
Seamlessly integrate automated TDScreen protocols alongside other essential screening and monitoring programs (additional fees may apply).
Yes. TDScreen is completely free for providers and patients to use. There are no hidden fees.
Any licensed prescribing behavioral health provider treating patients on antipsychotic medications — including psychiatrists, psychiatric NPs, etc. Commonly used in settings such as private clinics, community-based services like CCBHCs, hospitals, and more. Available for individual providers, group practices, and multi-site organizations. Full implementation support included.
Yes—patients find the experience quick, simple, and non-intimidating. Most complete the screen in under five minutes.
We have a very high level of predictability and sensitivity. We’re happy to share model cards or AUC data in a follow-up.
Most providers are live within 48 hours. For multi-provider or multi-site organizations, we’ll help onboard your team and align screening workflows.
A BAA is not required to use TDScreen, but it is necessary to access the full suite of features—including the Provider Portal, which offers real-time visibility into your patients’ results.
If you’re unable to sign a BAA, no problem—you can still use TDScreen! We’ll provide you with a unique, secure link to share with patients. They can use this link to access and complete the TDScreen independently, receive their results, and then share those results with you.
You will receive a clinically structured summary of their results, making it easy to determine next steps. TDScreen is designed to support—not replace—your clinical judgment and offers clear guidance for follow-up conversations.
Yes. There’s no contract, no cost, and no obligation. You’re free to discontinue at any time.
All provider-led TDScreen sessions are fully HIPAA-compliant and SOC 2 Type II certified. Patient data and PHI are protected in accordance with these standards.
For transparency, TDScreen also runs consumer-facing advertisements to raise awareness of tardive dyskinesia. Sessions originating from these ads use standard analytics tools such as Google and Meta, which may record site activity but never have access to video recordings or individual assessment results.
Learn what tardive dyskinesia is, how TDScreen works, and what to do if you’re concerned about your medication’s side effects.
Go to Patient Information Page →
